2025年

October 16, 2025: Announcement of Presentation in Academic Conference Regarding Result of Specified Clinical Trial using Digital Therapeutics for Tinnitus
October 1, 2025: KYORIN and Hinge Bio Enter into a Collaboration and License Agreement of HB2198 in Japan for SLE and other diseases
September 16, 2025: Topline Results from Phase 3 Clinical Study of KRP-R120 for Interstitial Lung Disease
July 31, 2025: Summary of Consolidated Financial Results (For the First Quarter ended June 30, 2025) [Under Japanese GAAP]
July 31, 2025: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2026
July 23, 2025: Launch of Beova Tablets in Thailand for Overactive Bladder
May 21, 2025: Notice of Dividends from Retained Earnings
May 12, 2025: Summary of Consolidated Financial Results(For fiscal year ended March 31, 2025) [Japanese GAAP]
May 12, 2025: Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (May 12 2025) - Supplementary Information
May 12, 2025: Notice Regarding Revision to Annual Dividend Forecast (Special Dividend)
May 12, 2025: Notice Regarding Cancellation of Treasury Stock
May 12, 2025: Announcement of Executive Personnel Changes
April 23, 2025: Notice of Upward Revisions to Earnings Forecasts
March 3, 2025: KYORIN and Novartis Enter into a Global License Agreement for KRP-M223
February 25, 2025: Digital Therapeutic Development for Chronic Cough Treatment
February 18, 2025: KYORIN and Cyrano Therapeutics Enter into an Option Agreement for CYR-064 for the Treatment of Post-Viral Loss of Smell in Japan
February 5, 2025: Consolidated Financial Results for Third Quarter of FY2024 - Supplementary Information
February 5, 2025: Consolidated Financial Results for the Nine Months Ended December 31, 2024) [Japanese GAAP]
January 14, 2025: KYORIN and BIODOL Enter Into Option Agreement for Novel Pain Treatment